Company / Inventory
Gilead Sciences Inventory History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Inventory
$1.8B
FY2025
5-year range
$1.5B / $1.8B
FY2021-FY2025
Trend
+3.7%
vs FY2024
Sector context
#13 of 105
Health Care
What the data says
Gilead Sciences's inventory of $1.8B is higher than 88% of companies in the Health Care sector (FY2025). Inventory has fluctuated over the past 10 years, ranging from $801M in FY2017 to $1.8B in FY2023.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +1.1%. Top quartile in the Health Care sector.
Remained stable around $1.8B over the past 2 years.
Health Care sector context is included.
Inventory over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- +1.1%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 105This company $1.8B Sector average $885.3M
▼
+100.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +1.1%, indicating consistent growth.
- In FY2025, inventory increased 3.7% year-over-year.
- Ranks #13 out of 105 companies in the Health Care sector.
- Peak inventory was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | InventoryValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +3.7% |
| FY2024 | $1.7B | -4.3% |
| FY2023 | $1.8B | +18.6% |
| FY2022 | $1.5B | -6.9% |
| FY2021 | $1.6B | -3.9% |
| FY2020 | $1.7B | +82.5% |
| FY2019 | $922.0M | +13.3% |
| FY2018 | $814.0M | +1.6% |
| FY2017 | $801.0M | -49.5% |
| FY2016 | $1.6B | -18.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026